Single-ingredient oral vitamin C × Relief of nasal symptoms in allergic rhinitis

Required evidence, verification status and materials actually read
Item	AVerification status	BReading scope	CReview item	DCurrent findings	EWhy unverified	FRequired materials and conditions	GFurther research
1	Partly verified	Full text not readStored summary read	N01 · Evidence conditionWhich allergic-rhinitis question is addressed?Required	The selected question is relief of nasal obstruction, discharge and sneezing. A clinical symptom comparison between oral monotherapy and suitable placebo is needed; intravenous treatment, combinations and skin markers are excluded from the direct effect. R01 R02	Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Adults with allergic rhinitis, single-ingredient oral C, nasal symptoms, rescue medication and placebo	Material needed: Original eligibility, intervention/comparator details, nasal-symptom/rescue-medication results and denominators are needed. This records needed materials; no new research was executed.
2	Partly verified	Full text not readStored summary read	N02 · Evidence conditionAre ascorbic acid, salt and tablet composition known?Required	The scope remains a single-ingredient ascorbic acid supplement, but study-specific salt, tablet/capsule, excipients, feedstock, process and country remain unverified. Equivalence of other products is not established. R01 R02	Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Single ingredient, salt, tablet/capsule, excipients, feedstock and manufacturing	Material needed: Original product names, ingredients, salts, excipients and manufacturing records are needed. This records needed materials; no new research was executed.
3	Partly verified	Full text not readStored summary read	N03 · Evidence conditionWhat is known about 1 g/day and actual exposure?Required	The main comparison is recorded as 1 g/day. Precise salt, tablet composition, frequency, actual use and adherence remain unverified. No active-dose conversion, recommended dose or cumulative dose is created. R01 R02	Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Main comparison dose, frequency, actual use and adherence	Material needed: Dosing, product, frequency, adherence, actual use and discontinuation records are needed. This records needed materials; no new research was executed.
4	Partly verified	Full text not readStored summary read	N04 · Evidence conditionAre the 1.5-year study-conduct period and individual dosing duration distinguished?Required	Individual dosing duration remains unverified. The original 1.5-year study-conduct period is not described as 1.5 years of treatment or long-term/persistent benefit. R01 R02	Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Study-conduct period, individual exposure, follow-up and symptom-assessment timing	Material needed: Original registration, recruitment/conduct dates, individual dosing, follow-up and assessment schedules are needed. This records needed materials; no new research was executed.
5	Partly verified	Full text not readStored summary read	N05 · Evidence conditionAre adult diagnosis, baseline symptoms and seasonality known?Required	The selected scope concerns adults with allergic rhinitis and direct oral monotherapy evidence. Detailed diagnosis, baseline symptoms, environment and arm composition remain unverified in stored summaries. R01 R02	Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Diagnosis, selection, baseline TNSS, allergens, season/environment and comorbidity	Material needed: Original diagnosis, selection/exclusion, baseline symptoms, season/environment, comorbidities and arm-composition tables are needed. This records needed materials; no new research was executed.
6	Partly verified	Full text not readStored summary read	N06 · Evidence conditionWhat were the sugar-placebo and comparable-care conditions?Required	The comparator is a sugar placebo tablet. Actual composition, masking and comparability of usual treatment, antihistamines, nasal medicines, rescue medication and lifestyle care remain unverified. R01 R02	Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Sugar-tablet composition, packaging, allocation/masking, concomitant care and rescue medication	Material needed: Original placebo, packaging, allocation/masking, concomitant treatment, rescue medication and lifestyle-care records are needed. This records needed materials; no new research was executed.
7	Partly verified	Full text not readStored summary read	N07 · Evidence conditionIs C alone separated from combined exercise, combinations and intravenous infusion?Required	Combined exercise, skin testing, intravenous and combination evidence remain distinct from the clinical symptom effect of oral C alone. Effects of exercise plus C are not converted into C-alone estimates. R01 R02	Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Original oral monotherapy contrast and separation of other interventions	Material needed: Original arms/intervention conditions and a separately identifiable monotherapy contrast are needed. Unidentified reports are not invented. This records needed materials; no new research was executed.
8	Partly verified	Full text not readStored summary read	N08 · Evidence conditionAre the 40 people and arm-specific analysis denominators known?Required	The original R01 sample size is 40. Exact arm-specific allocation, analysis, completion and endpoint denominators remain unverified. People are not arbitrarily divided into arms or added together. R01 R02	Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Overall size, arm allocation, analysis, completion and TNSS denominators	Material needed: Original arm-specific flow, allocation, analysis, completion and endpoint denominators are needed. No new attrition count is calculated. This records needed materials; no new research was executed.
9	Unverified	Full text not readStored summary read	N09 · Evidence conditionAre randomization and masking correctly left unverified?Required	R01 is recorded as a placebo-controlled human study, but randomization and masking remain unverified. An improvement abstract is not promoted to a verified randomized or masked trial. R01 R02	Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Allocation sequence, concealment and participant/assessor masking	Material needed: Original methods, registration, protocol and allocation/masking records are needed. No new official risk or certainty assessment is created. This records needed materials; no new research was executed.
10	Partly verified	Full text not readStored summary read	N10 · Evidence conditionWhat are the original total and individual nasal-symptom results?Required	The R01 stored summary retains the abstract conclusion of improvement, but exact between-group TNSS, effect size, CI and P remain unverified. No numerical improvement estimate is invented. R01 R02	Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Between-group estimates for TNSS, obstruction, discharge and sneezing	Material needed: Original endpoint definitions, between-group tables, baseline/change values, individual symptoms, denominators and assessment times are needed. This records needed materials; no new research was executed.
11	Unverified	Full text not readStored summary read	N11 · Evidence conditionAre rescue-medication outcomes distinguished from nasal symptoms?Required	The stored R01 result records that rescue-medication results are not provided. A symptom-improvement conclusion is not converted into reduced medication use. R01 R02	Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Rescue-medication type, rules, arm-specific use, denominators and timing	Material needed: Original rescue-medication conditions, amounts/frequency, denominators, timing and result tables are needed. This records needed materials; no new research was executed.
12	Unverified	Full text not readStored summary read	N12 · Evidence conditionAre gaps in effect size, 95% CI and P retained?Required	The original R01 between-group effect, CI and P remain unverified. Wording that leaves open a possibility is not converted into confirmation, a precise null or equivalence, and numbers are not reconstructed from the abstract. R01 R02	Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Exact effect, variance and uncertainty versus suitable placebo	Material needed: Original values, variance, arm denominators, model and CI/P are needed. No new effect or interval is calculated. This records needed materials; no new research was executed.
13	Unverified	Full text not readStored summary read	N13 · Evidence conditionAre prespecified 1st TNSS and reporting hierarchy known?Required	The existing endpoint record concerns symptoms/signs and plasma C; prespecified 1st TNSS designation remains unverified. The abstract alone does not establish a prospective hierarchy. R01 R02	Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Prespecified plans for TNSS, signs, plasma C and assessment times	Material needed: Original registration, protocol, analysis plan, endpoints/times and complete result tables are needed. This records needed materials; no new research was executed.
14	Unverified	Full text not readStored summary read	N14 · Evidence conditionWhat were symptom assessment, baseline adjustment and analysis sets?Required	Exact TNSS and analysis conditions in R01 remain unverified in stored summaries. No new scale, method, baseline adjustment or analysis set is assigned. R01 R02	Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Scale, assessor, baseline scores, final/change values and estimand	Material needed: Original assessments, times, baseline/adjustment, variance, allocation-based/completer analyses and statistical tables are needed. This records needed materials; no new research was executed.
15	Unverified	Full text not readStored summary read	N15 · Evidence conditionWhat is known about missingness, attrition and treatment changes?Required	The 40-person record does not provide exact arm-specific analysis denominators. Unread material is not converted into absence of missingness, attrition or treatment changes. R01 R02	Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Arm-specific flow, missing symptoms, attrition/exclusion and treatment changes	Material needed: Original flow, exclusion reasons, treatment changes, missing-data handling and sensitivity material are needed. This records needed materials; no new research was executed.
16	Partly verified	Full text not readStored summary read	N16 · Evidence conditionAre plasma C and histamine mechanisms distinguished from symptom effects?Supplementary	The original boundary is retained: plasma C and histamine mechanisms do not replace clinical symptom contrasts. No new equivalence to antihistamine treatment is established. R01 R02	Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Separate comparisons for plasma C, histamine and clinical nasal symptoms	Material needed: Direct nasal-symptom/rescue-medication comparisons and separate mechanistic-marker results are needed. This records needed materials; no new research was executed.
17	Partly verified	Full text not readStored summary read	N17 · Evidence conditionAre population and denominators from the 2025 skin-test study kept separate?Supplementary	R02 records 103 starting → 89 completing (C44/control45). These skin-test denominators are not pooled with clinical nasal-symptom trial denominators. R01 R02	Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Skin-test entry, completion, arm/endpoint denominators and diagnosis	Material needed: Original population, diagnosis, allocation/completion, skin-endpoint analysis denominators and attrition records are needed. No new attrition count or total is calculated. This records needed materials; no new research was executed.
18	Partly verified	Full text not readStored summary read	N18 · Evidence conditionAre histamine-wheal results retained accurately?Supplementary	The R02 histamine change is −2.5±11.57 versus −.92±14.24 mm², P=.56. The ± type remains unverified; this is not a nasal-symptom treatment result. R01 R02	Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Skin-wheal change in mm², original ±, P and timing	Material needed: Original dispersion definition, skin measurement, arms/times, denominators and intervals are needed. No new difference, CI or TNSS value is created. This records needed materials; no new research was executed.
19	Partly verified	Full text not readStored summary read	N19 · Evidence conditionAre dust-mite wheals also a separate skin outcome?Supplementary	The R02 dust-mite changes +4.48±25.08 versus −.16±26.17, P=.40 are retained. Histamine results and clinical nasal symptoms remain separate. R01 R02	Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Dust-mite wheal change, original ±, P and timing	Material needed: Original skin-result tables, units/dispersion, denominators, times, CI and prospective hierarchy are needed. Values are not converted into clinical effects. This records needed materials; no new research was executed.
20	Partly verified	Full text not readStored summary read	N20 · Evidence conditionIs a lack of skin-wheal difference kept separate from clinical replication or refutation?Required	The original description is retained: skin-wheal results are not direct replication or refutation of clinical nasal-symptom effects. Different outcomes are not merged into one TNSS conclusion. R01 R02	Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Directness boundary between surrogate markers and clinical nasal symptoms	Material needed: Direct replication evidence with the same population, oral monotherapy, clinical nasal symptoms and timing is needed. This records needed materials; no new research was executed.
21	Partly verified	Full text not readStored summary read	N21 · Evidence conditionAre the two reports distinguished from unique direct trials?Required	The structured reports concern the Munjal direct comparison and the Azhar skin-test study. They are not counted as two independent direct rhinitis replications. Final unique trial/participant counts remain unverified. R01 R02	Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Study families and overlap for the direct rhinitis comparison and skin-boundary report	Material needed: Original registration, samples, centres/times and additional-report mapping are needed. Reports are not added to create participant or trial totals. This records needed materials; no new research was executed.
22	Partly verified	Full text not readStored summary read	N22 · Evidence conditionAre unverified bibliography details of the 2025 report retained?Supplementary	The complete author list, PMID, DOI and registration for R02 remain unverified. A journal URL or historical abstract check is not promoted to current verification of the full bibliography or registration. R01 R02	Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Original complete author list, PMID, DOI and registration identifiers	Material needed: Original complete bibliography, registration, methods and result materials are needed. This records needed materials; no new research was executed.
23	Partly verified	Full text not readStored summary read	N23 · Evidence conditionAre the four company-involvement pathways known?Required	R01 funding, manufacturer, employee authors and conflicts, and R02 funding, remain unverified. I1 is the original assessment’s operational midpoint, not an independence strength. R01 R02	Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Funding, manufacturer/product support, employee authors and conflicts of interest	Material needed: Original funding, products, affiliations, conflict disclosures and team mapping are needed. Unverified involvement is not converted into no company involvement. This records needed materials; no new research was executed.
24	Partly verified	Full text not readStored summary read	N24 · Evidence conditionAre direct replication and persistent effects established?Supplementary	The original verdict description leaves between-group effect, precision and independence unverified. Other C indications or skin-test studies do not fill gaps in replication, efficacy or persistent effects. R01 R02	Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Unique replication trials with the same oral monotherapy and clinical endpoint	Material needed: Original trial families, products, duration, effects and denominators for the same question are needed. No new replication count is created. This records needed materials; no new research was executed.
25	Partly verified	Full text not readStored summary read	N25 · Evidence conditionAre harm collection, events and discontinuations known?Supplementary	Existing gastrointestinal caution with high oral C doses and limited trial-specific event records are retained. Actual incidence, collection methods and event causality are not added. R01 R02	Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Definitions, collection, severity and counts for diarrhea and gastrointestinal discomfort	Material needed: Original harm methods, events, discontinuations, omissions, comparator and period data are needed. Unread material is not treated as no harms. This records needed materials; no new research was executed.
26	Unverified	Full text not readStored summary read	N26 · Evidence conditionAre harm denominators, exposure and comparators distinguished?Supplementary	The 40 people in R01 and the R02 skin-test denominators do not establish safety denominators. Individual R01 exposure duration also remains unverified. R01 R02	Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Safety sets, actual use, events and individual exposure duration	Material needed: Arm-specific safety denominators, actual dosing/discontinuation, events, exposure and comparator data are needed. Incidence rates are not calculated. This records needed materials; no new research was executed.
27	Partly verified	Full text not readStored summary read	N27 · Evidence conditionAre stone, kidney-disease and iron-overload cautions distinguished from direct harms?Supplementary	Existing caution about stone risk, kidney disease and iron overload is retained. It is not converted into certification of trial harm occurrence, causality, contraindications or long-term safety. R01 R02	Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Vulnerable populations, concomitant use, alternative causes and long-term/rare harms	Material needed: Vulnerable groups, independent harm reports, exposure/denominators, concomitant use/alternative causes and event courses are needed. No new harm search or assessment is performed. This records needed materials; no new research was executed.
28	Partly verified	Full text not readStored summary read	N28 · Evidence conditionAre historical abstract checking and PDF failure separated from current unread status?Required	Historical R01 abstract/bibliography checking and PDF access failure, and R02 abstract/bibliography checking, remain historical. Stored summaries were read here; external abstracts, full text, registration and plans were not. R01 R02	Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Historical access descriptions, current stored summaries and external-material status	Material needed: Current external acquisition, actual reading and review remain outstanding. Historical failure is not converted into current inaccessibility, or historical checking into current reading. This records needed materials; no new research was executed.
29	Partly verified	Full text not readStored summary read	N29 · Evidence conditionAre original Korean/English descriptions and empty correction records preserved?Supplementary	Existing Korean/English descriptions and empty correction/detailed-claim records are preserved. No new correction or completed original-material clinical review is created. R01 R02	Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Complete Korean/English originals, empty corrections/detailed claims and original dates	Material needed: New evidence, corrections and verdict changes require preservation of originals and separate event records. This records needed materials; no new research was executed.
30	Partly verified	Full text not readStored summary read	N30 · Evidence conditionAre original C46, EX/CX and I1 distinguished from production?Required	The existing C·46 points·Caution, original rationale for EX/CX and the I1 operational midpoint, and evidence date 2026-09-07 are retained. Unverified information is not converted into no effect, a precise null, an independence strength or a new grade. R01 R02	Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	C46, Caution, assessment values, original exception rationale and evidence date	Material needed: New evidence, revised criteria and verdict changes are separate events. The existing date is not used as a current search or external-reading date. This records needed materials; no new research was executed.

No items match your search or filter.

30 itemsWhat the statuses mean

Assessment scope

Stored-material review date: Not recorded
Original evidence cut-off: 2026-09-07
Scope actually checked: Existing review summaries and stored records of methodological application. Full papers, supplements, registrations, plans and original data were not read.
What the dates mean: This is the date the stored materials were checked, not the date of a new search of the clinical literature.
Population: The selected scope is adults with allergic rhinitis. Detailed diagnosis, baseline nasal symptoms, allergens, season/environment, selection and comorbidity data remain unverified. Participants in the separate skin-test study are not automatically treated as the same clinical rhinitis population.
Ingredient, formulation and route: The intervention is a single-ingredient oral ascorbic acid supplement. Feedstock, process, country and study-specific salt, tablet/capsule, excipients and product remain unverified. Foods, combined exercise, combination products and intravenous infusion are excluded from the oral monotherapy effect.
Dose: The main comparison is recorded as 1 g/day. Precise salt, tablet composition, dosing frequency, actual use and adherence remain unverified. No active-dose conversion, cumulative dose, optimal dose or individual dosing guidance is created.
Comparator: The comparator is a sugar placebo tablet. Actual composition, packaging, allocation concealment, participant/assessor masking and comparability of antihistamines, nasal medicines, rescue medication and lifestyle care remain unverified. A placebo-comparison record is not promoted to verified randomization or masking.
Measured outcome: The endpoints are total nasal symptom score (TNSS), obstruction, discharge, sneezing and rescue-medication use. Prespecified primary (1st) TNSS, scale, timing, baseline adjustment, denominators and exact between-group effect, 95% CI and P remain unverified. Plasma C, histamine and dust-mite skin wheals are separate outcomes.
Duration: Individual dosing, follow-up and nasal-symptom assessment periods remain unverified. The 1.5-year study-conduct period is not converted into 1.5 years of individual use or long-term/persistent effects. Original dosing, recruitment/conduct and follow-up schedules must remain distinct.
Questions outside this scope: The selected question concerns single-ingredient oral C, nasal symptoms and rescue medication in adults with allergic rhinitis. It is not extended to combined exercise, combination products, intravenous infusion, skin markers or equivalence to antihistamines.; The existing C·46 points·Caution, assessment values, Korean/English descriptions, original rationale for the operational midpoint I1 and evidence date 2026-09-07 are retained. Unverified independence is not converted into a strength or new certification.; The 40 people in R01 do not establish arm-specific allocation, completion, TNSS analysis or safety denominators. R02 records 103 starting and 89 completing (C44/control45) in a separate skin-test study. Participant totals, arm sizes and new attrition counts are not calculated.; The 1.5-year study-conduct period in R01 remains distinct from unverified individual dosing duration. No 1.5-year treatment, long-term/persistent effect or cumulative dose is created.; Gaps in exact between-group TNSS, rescue medication, effect size, 95% CI and P remain. Numbers are not reconstructed from an improvement abstract, and unverified results are not converted into no effect, a precise null or equivalence.; Original skin-wheal changes, ± and P values from the separate study are retained. The ± type is not assumed, and a lack of skin-marker difference is not converted into direct clinical-symptom replication or refutation.; Existing caution about diarrhea, gastrointestinal discomfort, stone risk, kidney disease and iron overload with high oral C doses is retained. No new harm incidence, event causality, contraindication, long-term safety or individual dosing guidance is created.

Evidence and sources

The links below lead to the sources. A link alone does not mean the original source was read or its latest publication status verified.

R01 · Munjal et al. 2020 · Rhinitis placebo comparison

Official source

Material type: Placebo-controlled human study; randomization and masking unverified
Materials actually read: Stored existing review summary read; external material unread
Findings recorded in the stored summary: The historical abstract summary concludes improvement, but exact between-group TNSS, effect size, 95% CI, P and rescue-medication results remain unverified. The 1.5-year study-conduct period is not a 1.5-year individual treatment duration.
Record level: The original record concerns 40 people overall. Exact arm-specific allocation, analysis, completion and nasal-symptom/safety denominators remain unverified.
Study overlap and independent replication: The 2 stored evidence entries and 2 citations link to a direct rhinitis comparison and a separate skin-test study. They are not counted as two independent replications of the same question. Report mapping, sample overlap and final unique trial/participant counts remain unverified.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored existing review summary	Preserved copy of the complete existing review summary	Stored summary	Summary read	DOI 10.18203/issn.2454-5929.ijohns20204616. Historical journal abstract/bibliography checking and failed PDF access remain historical records. Stored summaries are read here; external abstracts, full text, registration and plans remain unread. Original material-specific dates and absent dates are retained without conversion into current external-reading dates.
External abstract	Original bibliographic link or needed material; external public availability/access status unverified	Unread; access not attempted	Not read	DOI 10.18203/issn.2454-5929.ijohns20204616. Historical journal abstract/bibliography checking and failed PDF access remain historical records. Stored summaries are read here; external abstracts, full text, registration and plans remain unread. Original material-specific dates and absent dates are retained without conversion into current external-reading dates.
External full text	Original bibliographic link or needed material; external public availability/access status unverified	Unread; access not attempted	Not read	DOI 10.18203/issn.2454-5929.ijohns20204616. Historical journal abstract/bibliography checking and failed PDF access remain historical records. Stored summaries are read here; external abstracts, full text, registration and plans remain unread. Original material-specific dates and absent dates are retained without conversion into current external-reading dates.
Registration material	Original bibliographic link or needed material; external public availability/access status unverified	Unread; access not attempted	Not read	DOI 10.18203/issn.2454-5929.ijohns20204616. Historical journal abstract/bibliography checking and failed PDF access remain historical records. Stored summaries are read here; external abstracts, full text, registration and plans remain unread. Original material-specific dates and absent dates are retained without conversion into current external-reading dates.
Protocol and analysis plan	Original bibliographic link or needed material; external public availability/access status unverified	Unread; access not attempted	Not read	DOI 10.18203/issn.2454-5929.ijohns20204616. Historical journal abstract/bibliography checking and failed PDF access remain historical records. Stored summaries are read here; external abstracts, full text, registration and plans remain unread. Original material-specific dates and absent dates are retained without conversion into current external-reading dates.

R02 · Azhar et al. 2025 · Histamine/dust-mite skin-test study

Official source

Material type: Randomized skin-test study; not direct rhinitis-symptom replication
Materials actually read: Stored existing review summary read; external material unread
Findings recorded in the stored summary: Histamine change −2.5±11.57 versus −.92±14.24 mm², P=.56; dust mite +4.48±25.08 versus −.16±26.17, P=.40. The ± type remains unverified; these are skin results rather than nasal-symptom treatment results.
Record level: The separate skin-test study records 103 starting → 89 completing (C44/control45). Endpoint-specific analysis denominators, attrition and diagnostic details remain unverified.
Study overlap and independent replication: The 2 stored evidence entries and 2 citations link to a direct rhinitis comparison and a separate skin-test study. They are not counted as two independent replications of the same question. Report mapping, sample overlap and final unique trial/participant counts remain unverified.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored existing review summary	Preserved copy of the complete existing review summary	Stored summary	Summary read	The complete author list, PMID, DOI and registration remain unverified in the original bibliography. The journal URL and historical abstract/bibliography checking do not establish current verification of the complete bibliography, registration or full text. Original material-specific dates and absent dates are retained without conversion into current external-reading dates.
External abstract	Original bibliographic link or needed material; external public availability/access status unverified	Unread; access not attempted	Not read	The complete author list, PMID, DOI and registration remain unverified in the original bibliography. The journal URL and historical abstract/bibliography checking do not establish current verification of the complete bibliography, registration or full text. Original material-specific dates and absent dates are retained without conversion into current external-reading dates.
External full text	Original bibliographic link or needed material; external public availability/access status unverified	Unread; access not attempted	Not read	The complete author list, PMID, DOI and registration remain unverified in the original bibliography. The journal URL and historical abstract/bibliography checking do not establish current verification of the complete bibliography, registration or full text. Original material-specific dates and absent dates are retained without conversion into current external-reading dates.
Registration material	Original bibliographic link or needed material; external public availability/access status unverified	Unread; access not attempted	Not read	The complete author list, PMID, DOI and registration remain unverified in the original bibliography. The journal URL and historical abstract/bibliography checking do not establish current verification of the complete bibliography, registration or full text. Original material-specific dates and absent dates are retained without conversion into current external-reading dates.
Protocol and analysis plan	Original bibliographic link or needed material; external public availability/access status unverified	Unread; access not attempted	Not read	The complete author list, PMID, DOI and registration remain unverified in the original bibliography. The journal URL and historical abstract/bibliography checking do not establish current verification of the complete bibliography, registration or full text. Original material-specific dates and absent dates are retained without conversion into current external-reading dates.

Report counts versus independent study counts

The 2 stored evidence entries and 2 citations link to a direct rhinitis comparison and a separate skin-test study. They are not counted as two independent replications of the same question. Report mapping, sample overlap and final unique trial/participant counts remain unverified.

Review criteria

Version 1.0 · Criteria record date 2026-10-06. These are Chamgap's own application conditions, informed by the referenced methods. They do not constitute official assessment-tool certification or a new efficacy score.

N01 · Which allergic-rhinitis question is addressed?

Required materials and conditions: Adults with allergic rhinitis, single-ingredient oral C, nasal symptoms, rescue medication and placebo
Conditions for verification: Original records on Adults with allergic rhinitis, single-ingredient oral C, nasal symptoms, rescue medication and placebo must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Requirement and applicability: Required
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Why this condition is needed: Material on Adults with allergic rhinitis, single-ingredient oral C, nasal symptoms, rescue medication and placebo is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

N02 · Are ascorbic acid, salt and tablet composition known?

Required materials and conditions: Single ingredient, salt, tablet/capsule, excipients, feedstock and manufacturing
Conditions for verification: Original records on Single ingredient, salt, tablet/capsule, excipients, feedstock and manufacturing must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Requirement and applicability: Required
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Why this condition is needed: Material on Single ingredient, salt, tablet/capsule, excipients, feedstock and manufacturing is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

N03 · What is known about 1 g/day and actual exposure?

Required materials and conditions: Main comparison dose, frequency, actual use and adherence
Conditions for verification: Original records on Main comparison dose, frequency, actual use and adherence must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Requirement and applicability: Required
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Why this condition is needed: Material on Main comparison dose, frequency, actual use and adherence is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

N04 · Are the 1.5-year study-conduct period and individual dosing duration distinguished?

Required materials and conditions: Study-conduct period, individual exposure, follow-up and symptom-assessment timing
Conditions for verification: Original records on Study-conduct period, individual exposure, follow-up and symptom-assessment timing must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Requirement and applicability: Required
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Why this condition is needed: Material on Study-conduct period, individual exposure, follow-up and symptom-assessment timing is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

N05 · Are adult diagnosis, baseline symptoms and seasonality known?

Required materials and conditions: Diagnosis, selection, baseline TNSS, allergens, season/environment and comorbidity
Conditions for verification: Original records on Diagnosis, selection, baseline TNSS, allergens, season/environment and comorbidity must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Requirement and applicability: Required
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Why this condition is needed: Material on Diagnosis, selection, baseline TNSS, allergens, season/environment and comorbidity is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

N06 · What were the sugar-placebo and comparable-care conditions?

Required materials and conditions: Sugar-tablet composition, packaging, allocation/masking, concomitant care and rescue medication
Conditions for verification: Original records on Sugar-tablet composition, packaging, allocation/masking, concomitant care and rescue medication must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Requirement and applicability: Required
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Why this condition is needed: Material on Sugar-tablet composition, packaging, allocation/masking, concomitant care and rescue medication is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

N07 · Is C alone separated from combined exercise, combinations and intravenous infusion?

Required materials and conditions: Original oral monotherapy contrast and separation of other interventions
Conditions for verification: Original records on Original oral monotherapy contrast and separation of other interventions must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Requirement and applicability: Required
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Why this condition is needed: Material on Original oral monotherapy contrast and separation of other interventions is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

N08 · Are the 40 people and arm-specific analysis denominators known?

Required materials and conditions: Overall size, arm allocation, analysis, completion and TNSS denominators
Conditions for verification: Original records on Overall size, arm allocation, analysis, completion and TNSS denominators must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Requirement and applicability: Required
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Why this condition is needed: Material on Overall size, arm allocation, analysis, completion and TNSS denominators is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

N09 · Are randomization and masking correctly left unverified?

Required materials and conditions: Allocation sequence, concealment and participant/assessor masking
Conditions for verification: Original records on Allocation sequence, concealment and participant/assessor masking must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Requirement and applicability: Required
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Why this condition is needed: Material on Allocation sequence, concealment and participant/assessor masking is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

N10 · What are the original total and individual nasal-symptom results?

Required materials and conditions: Between-group estimates for TNSS, obstruction, discharge and sneezing
Conditions for verification: Original records on Between-group estimates for TNSS, obstruction, discharge and sneezing must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Requirement and applicability: Required
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Why this condition is needed: Material on Between-group estimates for TNSS, obstruction, discharge and sneezing is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

N11 · Are rescue-medication outcomes distinguished from nasal symptoms?

Required materials and conditions: Rescue-medication type, rules, arm-specific use, denominators and timing
Conditions for verification: Original records on Rescue-medication type, rules, arm-specific use, denominators and timing must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Requirement and applicability: Required
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Why this condition is needed: Material on Rescue-medication type, rules, arm-specific use, denominators and timing is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

N12 · Are gaps in effect size, 95% CI and P retained?

Required materials and conditions: Exact effect, variance and uncertainty versus suitable placebo
Conditions for verification: Original records on Exact effect, variance and uncertainty versus suitable placebo must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Requirement and applicability: Required
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Why this condition is needed: Material on Exact effect, variance and uncertainty versus suitable placebo is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

N13 · Are prespecified 1st TNSS and reporting hierarchy known?

Required materials and conditions: Prespecified plans for TNSS, signs, plasma C and assessment times
Conditions for verification: Original records on Prespecified plans for TNSS, signs, plasma C and assessment times must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Requirement and applicability: Required
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Why this condition is needed: Material on Prespecified plans for TNSS, signs, plasma C and assessment times is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

N14 · What were symptom assessment, baseline adjustment and analysis sets?

Required materials and conditions: Scale, assessor, baseline scores, final/change values and estimand
Conditions for verification: Original records on Scale, assessor, baseline scores, final/change values and estimand must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Requirement and applicability: Required
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Why this condition is needed: Material on Scale, assessor, baseline scores, final/change values and estimand is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

N15 · What is known about missingness, attrition and treatment changes?

Required materials and conditions: Arm-specific flow, missing symptoms, attrition/exclusion and treatment changes
Conditions for verification: Original records on Arm-specific flow, missing symptoms, attrition/exclusion and treatment changes must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Requirement and applicability: Required
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Why this condition is needed: Material on Arm-specific flow, missing symptoms, attrition/exclusion and treatment changes is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

N16 · Are plasma C and histamine mechanisms distinguished from symptom effects?

Required materials and conditions: Separate comparisons for plasma C, histamine and clinical nasal symptoms
Conditions for verification: Original records on Separate comparisons for plasma C, histamine and clinical nasal symptoms must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Requirement and applicability: Supplementary
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Why this condition is needed: Material on Separate comparisons for plasma C, histamine and clinical nasal symptoms is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

N17 · Are population and denominators from the 2025 skin-test study kept separate?

Required materials and conditions: Skin-test entry, completion, arm/endpoint denominators and diagnosis
Conditions for verification: Original records on Skin-test entry, completion, arm/endpoint denominators and diagnosis must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Requirement and applicability: Supplementary
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Why this condition is needed: Material on Skin-test entry, completion, arm/endpoint denominators and diagnosis is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

N18 · Are histamine-wheal results retained accurately?

Required materials and conditions: Skin-wheal change in mm², original ±, P and timing
Conditions for verification: Original records on Skin-wheal change in mm², original ±, P and timing must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Requirement and applicability: Supplementary
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Why this condition is needed: Material on Skin-wheal change in mm², original ±, P and timing is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

N19 · Are dust-mite wheals also a separate skin outcome?

Required materials and conditions: Dust-mite wheal change, original ±, P and timing
Conditions for verification: Original records on Dust-mite wheal change, original ±, P and timing must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Requirement and applicability: Supplementary
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Why this condition is needed: Material on Dust-mite wheal change, original ±, P and timing is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

N20 · Is a lack of skin-wheal difference kept separate from clinical replication or refutation?

Required materials and conditions: Directness boundary between surrogate markers and clinical nasal symptoms
Conditions for verification: Original records on Directness boundary between surrogate markers and clinical nasal symptoms must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Requirement and applicability: Required
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Why this condition is needed: Material on Directness boundary between surrogate markers and clinical nasal symptoms is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

N21 · Are the two reports distinguished from unique direct trials?

Required materials and conditions: Study families and overlap for the direct rhinitis comparison and skin-boundary report
Conditions for verification: Original records on Study families and overlap for the direct rhinitis comparison and skin-boundary report must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Requirement and applicability: Required
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Why this condition is needed: Material on Study families and overlap for the direct rhinitis comparison and skin-boundary report is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

N22 · Are unverified bibliography details of the 2025 report retained?

Required materials and conditions: Original complete author list, PMID, DOI and registration identifiers
Conditions for verification: Original records on Original complete author list, PMID, DOI and registration identifiers must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Requirement and applicability: Supplementary
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Why this condition is needed: Material on Original complete author list, PMID, DOI and registration identifiers is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

N23 · Are the four company-involvement pathways known?

Required materials and conditions: Funding, manufacturer/product support, employee authors and conflicts of interest
Conditions for verification: Original records on Funding, manufacturer/product support, employee authors and conflicts of interest must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Requirement and applicability: Required
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Why this condition is needed: Material on Funding, manufacturer/product support, employee authors and conflicts of interest is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

N24 · Are direct replication and persistent effects established?

Required materials and conditions: Unique replication trials with the same oral monotherapy and clinical endpoint
Conditions for verification: Original records on Unique replication trials with the same oral monotherapy and clinical endpoint must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Requirement and applicability: Supplementary
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Why this condition is needed: Material on Unique replication trials with the same oral monotherapy and clinical endpoint is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

N25 · Are harm collection, events and discontinuations known?

Required materials and conditions: Definitions, collection, severity and counts for diarrhea and gastrointestinal discomfort
Conditions for verification: Original records on Definitions, collection, severity and counts for diarrhea and gastrointestinal discomfort must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Requirement and applicability: Supplementary
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Why this condition is needed: Material on Definitions, collection, severity and counts for diarrhea and gastrointestinal discomfort is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

N26 · Are harm denominators, exposure and comparators distinguished?

Required materials and conditions: Safety sets, actual use, events and individual exposure duration
Conditions for verification: Original records on Safety sets, actual use, events and individual exposure duration must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Requirement and applicability: Supplementary
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Why this condition is needed: Material on Safety sets, actual use, events and individual exposure duration is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

N27 · Are stone, kidney-disease and iron-overload cautions distinguished from direct harms?

Required materials and conditions: Vulnerable populations, concomitant use, alternative causes and long-term/rare harms
Conditions for verification: Original records on Vulnerable populations, concomitant use, alternative causes and long-term/rare harms must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Requirement and applicability: Supplementary
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Why this condition is needed: Material on Vulnerable populations, concomitant use, alternative causes and long-term/rare harms is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

N28 · Are historical abstract checking and PDF failure separated from current unread status?

Required materials and conditions: Historical access descriptions, current stored summaries and external-material status
Conditions for verification: Original records on Historical access descriptions, current stored summaries and external-material status must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Requirement and applicability: Required
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Why this condition is needed: Material on Historical access descriptions, current stored summaries and external-material status is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

N29 · Are original Korean/English descriptions and empty correction records preserved?

Required materials and conditions: Complete Korean/English originals, empty corrections/detailed claims and original dates
Conditions for verification: Original records on Complete Korean/English originals, empty corrections/detailed claims and original dates must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Requirement and applicability: Supplementary
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Why this condition is needed: Material on Complete Korean/English originals, empty corrections/detailed claims and original dates is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

N30 · Are original C46, EX/CX and I1 distinguished from production?

Required materials and conditions: C46, Caution, assessment values, original exception rationale and evidence date
Conditions for verification: Original records on C46, Caution, assessment values, original exception rationale and evidence date must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Requirement and applicability: Required
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Why this condition is needed: Material on C46, Caution, assessment values, original exception rationale and evidence date is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

Referenced methods and the sections actually reviewed

M03 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §3.1, §3.2.1–3.2.3, MECIR C5/C7/C13

Referenced principle: Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions.
Extent of review: Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

M04 · Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03

Official methodology · §4.5, §4.6.1–4.6.3, MECIR C42

Referenced principle: Distinguish studies from reports and link them; do not omit a study solely because results are unreported.
Extent of review: Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

M08 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §8.1–8.2.3, Table 8.2.a

Referenced principle: Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting.
Extent of review: Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

M15 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §15.2.4, §15.3.1–15.3.3

Referenced principle: Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision.
Extent of review: Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

M19 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §19.1.2, §19.2.1–19.2.4

Referenced principle: Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates.
Extent of review: Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

What the statuses mean

Partly verified: Partial information from the stored summary is linked; detailed originals and content review remain incomplete.
Unverified: Required details cannot be established within the preserved scope. This does not establish absence of effects or studies, or safety.
Review incomplete: Review of existing content remains incomplete.
Met: This state is used only within the relevant conditions after material verification and content review. It was not automatically assigned in this work.
Not reported: Unreported within material actually read. Unread external material is not relabeled as unreported.
Inaccessible: This means actual access failure. External access was not attempted in this work, so this state was not assigned.
Not applicable: Used only with an application exception and reason based on the question scope.
Conflicting data: This requires actual comparison of materials; no new conflict judgment was made in this work.
Insufficient evidence for the conditions: This indicates gaps in additional material for the selected conditions. Unread material as a whole is not converted into an efficacy grade.

Change history

2026-10-23 · Public page/material version 1.0

The public view and materials were prepared from the existing 30 items. No new clinical search, verification-state change or scoring was performed.

The stored-material review date (Not recorded) and original evidence cut-off (2026-09-07) were retained unchanged.

Researcher downloads

These materials provide the same evidence, scope and verification status as this page.

View all item details

N01 · Which allergic-rhinitis question is addressed?

Current findings: The selected question is relief of nasal obstruction, discharge and sneezing. A clinical symptom comparison between oral monotherapy and suitable placebo is needed; intravenous treatment, combinations and skin markers are excluded from the direct effect.
Verification status: Partly verified
Materials actually read: Existing Korean and English stored summaries, rhinitis comparison records and skin-test bibliography read; external abstracts, full text, registrations, protocols and analysis plans unread
Why unverified: Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Original eligibility, intervention/comparator details, nasal-symptom/rescue-medication results and denominators are needed.
Required materials and conditions: Adults with allergic rhinitis, single-ingredient oral C, nasal symptoms, rescue medication and placebo
Materials to obtain first: Original eligibility, intervention/comparator details, nasal-symptom/rescue-medication results and denominators are needed.
Further research: Material needed: Original eligibility, intervention/comparator details, nasal-symptom/rescue-medication results and denominators are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps in original diagnosis, products, individual exposure, arm-specific analyses, TNSS, rescue medication, plans, support and harms remain. Abstract-reported improvement is not converted into an established effect, a lack of skin-wheal difference into a clinical null or equivalence, or limited harm records into overall safety.
Conditions for verification: Original records on Adults with allergic rhinitis, single-ingredient oral C, nasal symptoms, rescue medication and placebo must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Why this condition is needed: Material on Adults with allergic rhinitis, single-ingredient oral C, nasal symptoms, rescue medication and placebo is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

Related sources R01 R02

N02 · Are ascorbic acid, salt and tablet composition known?

Current findings: The scope remains a single-ingredient ascorbic acid supplement, but study-specific salt, tablet/capsule, excipients, feedstock, process and country remain unverified. Equivalence of other products is not established.
Verification status: Partly verified
Materials actually read: Existing Korean and English stored summaries, rhinitis comparison records and skin-test bibliography read; external abstracts, full text, registrations, protocols and analysis plans unread
Why unverified: Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Original product names, ingredients, salts, excipients and manufacturing records are needed.
Required materials and conditions: Single ingredient, salt, tablet/capsule, excipients, feedstock and manufacturing
Materials to obtain first: Original product names, ingredients, salts, excipients and manufacturing records are needed.
Further research: Material needed: Original product names, ingredients, salts, excipients and manufacturing records are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps in original diagnosis, products, individual exposure, arm-specific analyses, TNSS, rescue medication, plans, support and harms remain. Abstract-reported improvement is not converted into an established effect, a lack of skin-wheal difference into a clinical null or equivalence, or limited harm records into overall safety.
Conditions for verification: Original records on Single ingredient, salt, tablet/capsule, excipients, feedstock and manufacturing must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Why this condition is needed: Material on Single ingredient, salt, tablet/capsule, excipients, feedstock and manufacturing is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

Related sources R01 R02

N03 · What is known about 1 g/day and actual exposure?

Current findings: The main comparison is recorded as 1 g/day. Precise salt, tablet composition, frequency, actual use and adherence remain unverified. No active-dose conversion, recommended dose or cumulative dose is created.
Verification status: Partly verified
Materials actually read: Existing Korean and English stored summaries, rhinitis comparison records and skin-test bibliography read; external abstracts, full text, registrations, protocols and analysis plans unread
Why unverified: Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Dosing, product, frequency, adherence, actual use and discontinuation records are needed.
Required materials and conditions: Main comparison dose, frequency, actual use and adherence
Materials to obtain first: Dosing, product, frequency, adherence, actual use and discontinuation records are needed.
Further research: Material needed: Dosing, product, frequency, adherence, actual use and discontinuation records are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps in original diagnosis, products, individual exposure, arm-specific analyses, TNSS, rescue medication, plans, support and harms remain. Abstract-reported improvement is not converted into an established effect, a lack of skin-wheal difference into a clinical null or equivalence, or limited harm records into overall safety.
Conditions for verification: Original records on Main comparison dose, frequency, actual use and adherence must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Why this condition is needed: Material on Main comparison dose, frequency, actual use and adherence is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

Related sources R01 R02

N04 · Are the 1.5-year study-conduct period and individual dosing duration distinguished?

Current findings: Individual dosing duration remains unverified. The original 1.5-year study-conduct period is not described as 1.5 years of treatment or long-term/persistent benefit.
Verification status: Partly verified
Materials actually read: Existing Korean and English stored summaries, rhinitis comparison records and skin-test bibliography read; external abstracts, full text, registrations, protocols and analysis plans unread
Why unverified: Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Original registration, recruitment/conduct dates, individual dosing, follow-up and assessment schedules are needed.
Required materials and conditions: Study-conduct period, individual exposure, follow-up and symptom-assessment timing
Materials to obtain first: Original registration, recruitment/conduct dates, individual dosing, follow-up and assessment schedules are needed.
Further research: Material needed: Original registration, recruitment/conduct dates, individual dosing, follow-up and assessment schedules are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps in original diagnosis, products, individual exposure, arm-specific analyses, TNSS, rescue medication, plans, support and harms remain. Abstract-reported improvement is not converted into an established effect, a lack of skin-wheal difference into a clinical null or equivalence, or limited harm records into overall safety.
Conditions for verification: Original records on Study-conduct period, individual exposure, follow-up and symptom-assessment timing must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Why this condition is needed: Material on Study-conduct period, individual exposure, follow-up and symptom-assessment timing is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

Related sources R01 R02

N05 · Are adult diagnosis, baseline symptoms and seasonality known?

Current findings: The selected scope concerns adults with allergic rhinitis and direct oral monotherapy evidence. Detailed diagnosis, baseline symptoms, environment and arm composition remain unverified in stored summaries.
Verification status: Partly verified
Materials actually read: Existing Korean and English stored summaries, rhinitis comparison records and skin-test bibliography read; external abstracts, full text, registrations, protocols and analysis plans unread
Why unverified: Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Original diagnosis, selection/exclusion, baseline symptoms, season/environment, comorbidities and arm-composition tables are needed.
Required materials and conditions: Diagnosis, selection, baseline TNSS, allergens, season/environment and comorbidity
Materials to obtain first: Original diagnosis, selection/exclusion, baseline symptoms, season/environment, comorbidities and arm-composition tables are needed.
Further research: Material needed: Original diagnosis, selection/exclusion, baseline symptoms, season/environment, comorbidities and arm-composition tables are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps in original diagnosis, products, individual exposure, arm-specific analyses, TNSS, rescue medication, plans, support and harms remain. Abstract-reported improvement is not converted into an established effect, a lack of skin-wheal difference into a clinical null or equivalence, or limited harm records into overall safety.
Conditions for verification: Original records on Diagnosis, selection, baseline TNSS, allergens, season/environment and comorbidity must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Why this condition is needed: Material on Diagnosis, selection, baseline TNSS, allergens, season/environment and comorbidity is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

Related sources R01 R02

N06 · What were the sugar-placebo and comparable-care conditions?

Current findings: The comparator is a sugar placebo tablet. Actual composition, masking and comparability of usual treatment, antihistamines, nasal medicines, rescue medication and lifestyle care remain unverified.
Verification status: Partly verified
Materials actually read: Existing Korean and English stored summaries, rhinitis comparison records and skin-test bibliography read; external abstracts, full text, registrations, protocols and analysis plans unread
Why unverified: Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Original placebo, packaging, allocation/masking, concomitant treatment, rescue medication and lifestyle-care records are needed.
Required materials and conditions: Sugar-tablet composition, packaging, allocation/masking, concomitant care and rescue medication
Materials to obtain first: Original placebo, packaging, allocation/masking, concomitant treatment, rescue medication and lifestyle-care records are needed.
Further research: Material needed: Original placebo, packaging, allocation/masking, concomitant treatment, rescue medication and lifestyle-care records are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps in original diagnosis, products, individual exposure, arm-specific analyses, TNSS, rescue medication, plans, support and harms remain. Abstract-reported improvement is not converted into an established effect, a lack of skin-wheal difference into a clinical null or equivalence, or limited harm records into overall safety.
Conditions for verification: Original records on Sugar-tablet composition, packaging, allocation/masking, concomitant care and rescue medication must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Why this condition is needed: Material on Sugar-tablet composition, packaging, allocation/masking, concomitant care and rescue medication is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

Related sources R01 R02

N07 · Is C alone separated from combined exercise, combinations and intravenous infusion?

Current findings: Combined exercise, skin testing, intravenous and combination evidence remain distinct from the clinical symptom effect of oral C alone. Effects of exercise plus C are not converted into C-alone estimates.
Verification status: Partly verified
Materials actually read: Existing Korean and English stored summaries, rhinitis comparison records and skin-test bibliography read; external abstracts, full text, registrations, protocols and analysis plans unread
Why unverified: Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Original arms/intervention conditions and a separately identifiable monotherapy contrast are needed. Unidentified reports are not invented.
Required materials and conditions: Original oral monotherapy contrast and separation of other interventions
Materials to obtain first: Original arms/intervention conditions and a separately identifiable monotherapy contrast are needed. Unidentified reports are not invented.
Further research: Material needed: Original arms/intervention conditions and a separately identifiable monotherapy contrast are needed. Unidentified reports are not invented. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps in original diagnosis, products, individual exposure, arm-specific analyses, TNSS, rescue medication, plans, support and harms remain. Abstract-reported improvement is not converted into an established effect, a lack of skin-wheal difference into a clinical null or equivalence, or limited harm records into overall safety.
Conditions for verification: Original records on Original oral monotherapy contrast and separation of other interventions must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Why this condition is needed: Material on Original oral monotherapy contrast and separation of other interventions is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

Related sources R01 R02

N08 · Are the 40 people and arm-specific analysis denominators known?

Current findings: The original R01 sample size is 40. Exact arm-specific allocation, analysis, completion and endpoint denominators remain unverified. People are not arbitrarily divided into arms or added together.
Verification status: Partly verified
Materials actually read: Existing Korean and English stored summaries, rhinitis comparison records and skin-test bibliography read; external abstracts, full text, registrations, protocols and analysis plans unread
Why unverified: Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Original arm-specific flow, allocation, analysis, completion and endpoint denominators are needed. No new attrition count is calculated.
Required materials and conditions: Overall size, arm allocation, analysis, completion and TNSS denominators
Materials to obtain first: Original arm-specific flow, allocation, analysis, completion and endpoint denominators are needed. No new attrition count is calculated.
Further research: Material needed: Original arm-specific flow, allocation, analysis, completion and endpoint denominators are needed. No new attrition count is calculated. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps in original diagnosis, products, individual exposure, arm-specific analyses, TNSS, rescue medication, plans, support and harms remain. Abstract-reported improvement is not converted into an established effect, a lack of skin-wheal difference into a clinical null or equivalence, or limited harm records into overall safety.
Conditions for verification: Original records on Overall size, arm allocation, analysis, completion and TNSS denominators must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Why this condition is needed: Material on Overall size, arm allocation, analysis, completion and TNSS denominators is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

Related sources R01 R02

N09 · Are randomization and masking correctly left unverified?

Current findings: R01 is recorded as a placebo-controlled human study, but randomization and masking remain unverified. An improvement abstract is not promoted to a verified randomized or masked trial.
Verification status: Unverified
Materials actually read: Existing Korean and English stored summaries, rhinitis comparison records and skin-test bibliography read; external abstracts, full text, registrations, protocols and analysis plans unread
Why unverified: Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Original methods, registration, protocol and allocation/masking records are needed. No new official risk or certainty assessment is created.
Required materials and conditions: Allocation sequence, concealment and participant/assessor masking
Materials to obtain first: Original methods, registration, protocol and allocation/masking records are needed. No new official risk or certainty assessment is created.
Further research: Material needed: Original methods, registration, protocol and allocation/masking records are needed. No new official risk or certainty assessment is created. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps in original diagnosis, products, individual exposure, arm-specific analyses, TNSS, rescue medication, plans, support and harms remain. Abstract-reported improvement is not converted into an established effect, a lack of skin-wheal difference into a clinical null or equivalence, or limited harm records into overall safety.
Conditions for verification: Original records on Allocation sequence, concealment and participant/assessor masking must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Why this condition is needed: Material on Allocation sequence, concealment and participant/assessor masking is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

Related sources R01 R02

N10 · What are the original total and individual nasal-symptom results?

Current findings: The R01 stored summary retains the abstract conclusion of improvement, but exact between-group TNSS, effect size, CI and P remain unverified. No numerical improvement estimate is invented.
Verification status: Partly verified
Materials actually read: Existing Korean and English stored summaries, rhinitis comparison records and skin-test bibliography read; external abstracts, full text, registrations, protocols and analysis plans unread
Why unverified: Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Original endpoint definitions, between-group tables, baseline/change values, individual symptoms, denominators and assessment times are needed.
Required materials and conditions: Between-group estimates for TNSS, obstruction, discharge and sneezing
Materials to obtain first: Original endpoint definitions, between-group tables, baseline/change values, individual symptoms, denominators and assessment times are needed.
Further research: Material needed: Original endpoint definitions, between-group tables, baseline/change values, individual symptoms, denominators and assessment times are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps in original diagnosis, products, individual exposure, arm-specific analyses, TNSS, rescue medication, plans, support and harms remain. Abstract-reported improvement is not converted into an established effect, a lack of skin-wheal difference into a clinical null or equivalence, or limited harm records into overall safety.
Conditions for verification: Original records on Between-group estimates for TNSS, obstruction, discharge and sneezing must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Why this condition is needed: Material on Between-group estimates for TNSS, obstruction, discharge and sneezing is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

Related sources R01 R02

N11 · Are rescue-medication outcomes distinguished from nasal symptoms?

Current findings: The stored R01 result records that rescue-medication results are not provided. A symptom-improvement conclusion is not converted into reduced medication use.
Verification status: Unverified
Materials actually read: Existing Korean and English stored summaries, rhinitis comparison records and skin-test bibliography read; external abstracts, full text, registrations, protocols and analysis plans unread
Why unverified: Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Original rescue-medication conditions, amounts/frequency, denominators, timing and result tables are needed.
Required materials and conditions: Rescue-medication type, rules, arm-specific use, denominators and timing
Materials to obtain first: Original rescue-medication conditions, amounts/frequency, denominators, timing and result tables are needed.
Further research: Material needed: Original rescue-medication conditions, amounts/frequency, denominators, timing and result tables are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps in original diagnosis, products, individual exposure, arm-specific analyses, TNSS, rescue medication, plans, support and harms remain. Abstract-reported improvement is not converted into an established effect, a lack of skin-wheal difference into a clinical null or equivalence, or limited harm records into overall safety.
Conditions for verification: Original records on Rescue-medication type, rules, arm-specific use, denominators and timing must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Why this condition is needed: Material on Rescue-medication type, rules, arm-specific use, denominators and timing is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

Related sources R01 R02

N12 · Are gaps in effect size, 95% CI and P retained?

Current findings: The original R01 between-group effect, CI and P remain unverified. Wording that leaves open a possibility is not converted into confirmation, a precise null or equivalence, and numbers are not reconstructed from the abstract.
Verification status: Unverified
Materials actually read: Existing Korean and English stored summaries, rhinitis comparison records and skin-test bibliography read; external abstracts, full text, registrations, protocols and analysis plans unread
Why unverified: Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Original values, variance, arm denominators, model and CI/P are needed. No new effect or interval is calculated.
Required materials and conditions: Exact effect, variance and uncertainty versus suitable placebo
Materials to obtain first: Original values, variance, arm denominators, model and CI/P are needed. No new effect or interval is calculated.
Further research: Material needed: Original values, variance, arm denominators, model and CI/P are needed. No new effect or interval is calculated. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps in original diagnosis, products, individual exposure, arm-specific analyses, TNSS, rescue medication, plans, support and harms remain. Abstract-reported improvement is not converted into an established effect, a lack of skin-wheal difference into a clinical null or equivalence, or limited harm records into overall safety.
Conditions for verification: Original records on Exact effect, variance and uncertainty versus suitable placebo must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Why this condition is needed: Material on Exact effect, variance and uncertainty versus suitable placebo is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

Related sources R01 R02

N13 · Are prespecified 1st TNSS and reporting hierarchy known?

Current findings: The existing endpoint record concerns symptoms/signs and plasma C; prespecified 1st TNSS designation remains unverified. The abstract alone does not establish a prospective hierarchy.
Verification status: Unverified
Materials actually read: Existing Korean and English stored summaries, rhinitis comparison records and skin-test bibliography read; external abstracts, full text, registrations, protocols and analysis plans unread
Why unverified: Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Original registration, protocol, analysis plan, endpoints/times and complete result tables are needed.
Required materials and conditions: Prespecified plans for TNSS, signs, plasma C and assessment times
Materials to obtain first: Original registration, protocol, analysis plan, endpoints/times and complete result tables are needed.
Further research: Material needed: Original registration, protocol, analysis plan, endpoints/times and complete result tables are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps in original diagnosis, products, individual exposure, arm-specific analyses, TNSS, rescue medication, plans, support and harms remain. Abstract-reported improvement is not converted into an established effect, a lack of skin-wheal difference into a clinical null or equivalence, or limited harm records into overall safety.
Conditions for verification: Original records on Prespecified plans for TNSS, signs, plasma C and assessment times must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Why this condition is needed: Material on Prespecified plans for TNSS, signs, plasma C and assessment times is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

Related sources R01 R02

N14 · What were symptom assessment, baseline adjustment and analysis sets?

Current findings: Exact TNSS and analysis conditions in R01 remain unverified in stored summaries. No new scale, method, baseline adjustment or analysis set is assigned.
Verification status: Unverified
Materials actually read: Existing Korean and English stored summaries, rhinitis comparison records and skin-test bibliography read; external abstracts, full text, registrations, protocols and analysis plans unread
Why unverified: Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Original assessments, times, baseline/adjustment, variance, allocation-based/completer analyses and statistical tables are needed.
Required materials and conditions: Scale, assessor, baseline scores, final/change values and estimand
Materials to obtain first: Original assessments, times, baseline/adjustment, variance, allocation-based/completer analyses and statistical tables are needed.
Further research: Material needed: Original assessments, times, baseline/adjustment, variance, allocation-based/completer analyses and statistical tables are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps in original diagnosis, products, individual exposure, arm-specific analyses, TNSS, rescue medication, plans, support and harms remain. Abstract-reported improvement is not converted into an established effect, a lack of skin-wheal difference into a clinical null or equivalence, or limited harm records into overall safety.
Conditions for verification: Original records on Scale, assessor, baseline scores, final/change values and estimand must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Why this condition is needed: Material on Scale, assessor, baseline scores, final/change values and estimand is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

Related sources R01 R02

N15 · What is known about missingness, attrition and treatment changes?

Current findings: The 40-person record does not provide exact arm-specific analysis denominators. Unread material is not converted into absence of missingness, attrition or treatment changes.
Verification status: Unverified
Materials actually read: Existing Korean and English stored summaries, rhinitis comparison records and skin-test bibliography read; external abstracts, full text, registrations, protocols and analysis plans unread
Why unverified: Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Original flow, exclusion reasons, treatment changes, missing-data handling and sensitivity material are needed.
Required materials and conditions: Arm-specific flow, missing symptoms, attrition/exclusion and treatment changes
Materials to obtain first: Original flow, exclusion reasons, treatment changes, missing-data handling and sensitivity material are needed.
Further research: Material needed: Original flow, exclusion reasons, treatment changes, missing-data handling and sensitivity material are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps in original diagnosis, products, individual exposure, arm-specific analyses, TNSS, rescue medication, plans, support and harms remain. Abstract-reported improvement is not converted into an established effect, a lack of skin-wheal difference into a clinical null or equivalence, or limited harm records into overall safety.
Conditions for verification: Original records on Arm-specific flow, missing symptoms, attrition/exclusion and treatment changes must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Why this condition is needed: Material on Arm-specific flow, missing symptoms, attrition/exclusion and treatment changes is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

Related sources R01 R02

N16 · Are plasma C and histamine mechanisms distinguished from symptom effects?

Current findings: The original boundary is retained: plasma C and histamine mechanisms do not replace clinical symptom contrasts. No new equivalence to antihistamine treatment is established.
Verification status: Partly verified
Materials actually read: Existing Korean and English stored summaries, rhinitis comparison records and skin-test bibliography read; external abstracts, full text, registrations, protocols and analysis plans unread
Why unverified: Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Direct nasal-symptom/rescue-medication comparisons and separate mechanistic-marker results are needed.
Required materials and conditions: Separate comparisons for plasma C, histamine and clinical nasal symptoms
Materials to obtain first: Direct nasal-symptom/rescue-medication comparisons and separate mechanistic-marker results are needed.
Further research: Material needed: Direct nasal-symptom/rescue-medication comparisons and separate mechanistic-marker results are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps in original diagnosis, products, individual exposure, arm-specific analyses, TNSS, rescue medication, plans, support and harms remain. Abstract-reported improvement is not converted into an established effect, a lack of skin-wheal difference into a clinical null or equivalence, or limited harm records into overall safety.
Conditions for verification: Original records on Separate comparisons for plasma C, histamine and clinical nasal symptoms must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Why this condition is needed: Material on Separate comparisons for plasma C, histamine and clinical nasal symptoms is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

Related sources R01 R02

N17 · Are population and denominators from the 2025 skin-test study kept separate?

Current findings: R02 records 103 starting → 89 completing (C44/control45). These skin-test denominators are not pooled with clinical nasal-symptom trial denominators.
Verification status: Partly verified
Materials actually read: Existing Korean and English stored summaries, rhinitis comparison records and skin-test bibliography read; external abstracts, full text, registrations, protocols and analysis plans unread
Why unverified: Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Original population, diagnosis, allocation/completion, skin-endpoint analysis denominators and attrition records are needed. No new attrition count or total is calculated.
Required materials and conditions: Skin-test entry, completion, arm/endpoint denominators and diagnosis
Materials to obtain first: Original population, diagnosis, allocation/completion, skin-endpoint analysis denominators and attrition records are needed. No new attrition count or total is calculated.
Further research: Material needed: Original population, diagnosis, allocation/completion, skin-endpoint analysis denominators and attrition records are needed. No new attrition count or total is calculated. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps in original diagnosis, products, individual exposure, arm-specific analyses, TNSS, rescue medication, plans, support and harms remain. Abstract-reported improvement is not converted into an established effect, a lack of skin-wheal difference into a clinical null or equivalence, or limited harm records into overall safety.
Conditions for verification: Original records on Skin-test entry, completion, arm/endpoint denominators and diagnosis must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Why this condition is needed: Material on Skin-test entry, completion, arm/endpoint denominators and diagnosis is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

Related sources R01 R02

N18 · Are histamine-wheal results retained accurately?

Current findings: The R02 histamine change is −2.5±11.57 versus −.92±14.24 mm², P=.56. The ± type remains unverified; this is not a nasal-symptom treatment result.
Verification status: Partly verified
Materials actually read: Existing Korean and English stored summaries, rhinitis comparison records and skin-test bibliography read; external abstracts, full text, registrations, protocols and analysis plans unread
Why unverified: Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Original dispersion definition, skin measurement, arms/times, denominators and intervals are needed. No new difference, CI or TNSS value is created.
Required materials and conditions: Skin-wheal change in mm², original ±, P and timing
Materials to obtain first: Original dispersion definition, skin measurement, arms/times, denominators and intervals are needed. No new difference, CI or TNSS value is created.
Further research: Material needed: Original dispersion definition, skin measurement, arms/times, denominators and intervals are needed. No new difference, CI or TNSS value is created. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps in original diagnosis, products, individual exposure, arm-specific analyses, TNSS, rescue medication, plans, support and harms remain. Abstract-reported improvement is not converted into an established effect, a lack of skin-wheal difference into a clinical null or equivalence, or limited harm records into overall safety.
Conditions for verification: Original records on Skin-wheal change in mm², original ±, P and timing must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Why this condition is needed: Material on Skin-wheal change in mm², original ±, P and timing is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

Related sources R01 R02

N19 · Are dust-mite wheals also a separate skin outcome?

Current findings: The R02 dust-mite changes +4.48±25.08 versus −.16±26.17, P=.40 are retained. Histamine results and clinical nasal symptoms remain separate.
Verification status: Partly verified
Materials actually read: Existing Korean and English stored summaries, rhinitis comparison records and skin-test bibliography read; external abstracts, full text, registrations, protocols and analysis plans unread
Why unverified: Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Original skin-result tables, units/dispersion, denominators, times, CI and prospective hierarchy are needed. Values are not converted into clinical effects.
Required materials and conditions: Dust-mite wheal change, original ±, P and timing
Materials to obtain first: Original skin-result tables, units/dispersion, denominators, times, CI and prospective hierarchy are needed. Values are not converted into clinical effects.
Further research: Material needed: Original skin-result tables, units/dispersion, denominators, times, CI and prospective hierarchy are needed. Values are not converted into clinical effects. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps in original diagnosis, products, individual exposure, arm-specific analyses, TNSS, rescue medication, plans, support and harms remain. Abstract-reported improvement is not converted into an established effect, a lack of skin-wheal difference into a clinical null or equivalence, or limited harm records into overall safety.
Conditions for verification: Original records on Dust-mite wheal change, original ±, P and timing must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Why this condition is needed: Material on Dust-mite wheal change, original ±, P and timing is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

Related sources R01 R02

N20 · Is a lack of skin-wheal difference kept separate from clinical replication or refutation?

Current findings: The original description is retained: skin-wheal results are not direct replication or refutation of clinical nasal-symptom effects. Different outcomes are not merged into one TNSS conclusion.
Verification status: Partly verified
Materials actually read: Existing Korean and English stored summaries, rhinitis comparison records and skin-test bibliography read; external abstracts, full text, registrations, protocols and analysis plans unread
Why unverified: Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Direct replication evidence with the same population, oral monotherapy, clinical nasal symptoms and timing is needed.
Required materials and conditions: Directness boundary between surrogate markers and clinical nasal symptoms
Materials to obtain first: Direct replication evidence with the same population, oral monotherapy, clinical nasal symptoms and timing is needed.
Further research: Material needed: Direct replication evidence with the same population, oral monotherapy, clinical nasal symptoms and timing is needed. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps in original diagnosis, products, individual exposure, arm-specific analyses, TNSS, rescue medication, plans, support and harms remain. Abstract-reported improvement is not converted into an established effect, a lack of skin-wheal difference into a clinical null or equivalence, or limited harm records into overall safety.
Conditions for verification: Original records on Directness boundary between surrogate markers and clinical nasal symptoms must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Why this condition is needed: Material on Directness boundary between surrogate markers and clinical nasal symptoms is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

Related sources R01 R02

N21 · Are the two reports distinguished from unique direct trials?

Current findings: The structured reports concern the Munjal direct comparison and the Azhar skin-test study. They are not counted as two independent direct rhinitis replications. Final unique trial/participant counts remain unverified.
Verification status: Partly verified
Materials actually read: Existing Korean and English stored summaries, rhinitis comparison records and skin-test bibliography read; external abstracts, full text, registrations, protocols and analysis plans unread
Why unverified: Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Original registration, samples, centres/times and additional-report mapping are needed. Reports are not added to create participant or trial totals.
Required materials and conditions: Study families and overlap for the direct rhinitis comparison and skin-boundary report
Materials to obtain first: Original registration, samples, centres/times and additional-report mapping are needed. Reports are not added to create participant or trial totals.
Further research: Material needed: Original registration, samples, centres/times and additional-report mapping are needed. Reports are not added to create participant or trial totals. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps in original diagnosis, products, individual exposure, arm-specific analyses, TNSS, rescue medication, plans, support and harms remain. Abstract-reported improvement is not converted into an established effect, a lack of skin-wheal difference into a clinical null or equivalence, or limited harm records into overall safety.
Conditions for verification: Original records on Study families and overlap for the direct rhinitis comparison and skin-boundary report must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Why this condition is needed: Material on Study families and overlap for the direct rhinitis comparison and skin-boundary report is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

Related sources R01 R02

N22 · Are unverified bibliography details of the 2025 report retained?

Current findings: The complete author list, PMID, DOI and registration for R02 remain unverified. A journal URL or historical abstract check is not promoted to current verification of the full bibliography or registration.
Verification status: Partly verified
Materials actually read: Existing Korean and English stored summaries, rhinitis comparison records and skin-test bibliography read; external abstracts, full text, registrations, protocols and analysis plans unread
Why unverified: Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Original complete bibliography, registration, methods and result materials are needed.
Required materials and conditions: Original complete author list, PMID, DOI and registration identifiers
Materials to obtain first: Original complete bibliography, registration, methods and result materials are needed.
Further research: Material needed: Original complete bibliography, registration, methods and result materials are needed. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps in original diagnosis, products, individual exposure, arm-specific analyses, TNSS, rescue medication, plans, support and harms remain. Abstract-reported improvement is not converted into an established effect, a lack of skin-wheal difference into a clinical null or equivalence, or limited harm records into overall safety.
Conditions for verification: Original records on Original complete author list, PMID, DOI and registration identifiers must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Why this condition is needed: Material on Original complete author list, PMID, DOI and registration identifiers is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

Related sources R01 R02

N23 · Are the four company-involvement pathways known?

Current findings: R01 funding, manufacturer, employee authors and conflicts, and R02 funding, remain unverified. I1 is the original assessment’s operational midpoint, not an independence strength.
Verification status: Partly verified
Materials actually read: Existing Korean and English stored summaries, rhinitis comparison records and skin-test bibliography read; external abstracts, full text, registrations, protocols and analysis plans unread
Why unverified: Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Original funding, products, affiliations, conflict disclosures and team mapping are needed. Unverified involvement is not converted into no company involvement.
Required materials and conditions: Funding, manufacturer/product support, employee authors and conflicts of interest
Materials to obtain first: Original funding, products, affiliations, conflict disclosures and team mapping are needed. Unverified involvement is not converted into no company involvement.
Further research: Material needed: Original funding, products, affiliations, conflict disclosures and team mapping are needed. Unverified involvement is not converted into no company involvement. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps in original diagnosis, products, individual exposure, arm-specific analyses, TNSS, rescue medication, plans, support and harms remain. Abstract-reported improvement is not converted into an established effect, a lack of skin-wheal difference into a clinical null or equivalence, or limited harm records into overall safety.
Conditions for verification: Original records on Funding, manufacturer/product support, employee authors and conflicts of interest must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Why this condition is needed: Material on Funding, manufacturer/product support, employee authors and conflicts of interest is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

Related sources R01 R02

N24 · Are direct replication and persistent effects established?

Current findings: The original verdict description leaves between-group effect, precision and independence unverified. Other C indications or skin-test studies do not fill gaps in replication, efficacy or persistent effects.
Verification status: Partly verified
Materials actually read: Existing Korean and English stored summaries, rhinitis comparison records and skin-test bibliography read; external abstracts, full text, registrations, protocols and analysis plans unread
Why unverified: Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Original trial families, products, duration, effects and denominators for the same question are needed. No new replication count is created.
Required materials and conditions: Unique replication trials with the same oral monotherapy and clinical endpoint
Materials to obtain first: Original trial families, products, duration, effects and denominators for the same question are needed. No new replication count is created.
Further research: Material needed: Original trial families, products, duration, effects and denominators for the same question are needed. No new replication count is created. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps in original diagnosis, products, individual exposure, arm-specific analyses, TNSS, rescue medication, plans, support and harms remain. Abstract-reported improvement is not converted into an established effect, a lack of skin-wheal difference into a clinical null or equivalence, or limited harm records into overall safety.
Conditions for verification: Original records on Unique replication trials with the same oral monotherapy and clinical endpoint must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Why this condition is needed: Material on Unique replication trials with the same oral monotherapy and clinical endpoint is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

Related sources R01 R02

N25 · Are harm collection, events and discontinuations known?

Current findings: Existing gastrointestinal caution with high oral C doses and limited trial-specific event records are retained. Actual incidence, collection methods and event causality are not added.
Verification status: Partly verified
Materials actually read: Existing Korean and English stored summaries, rhinitis comparison records and skin-test bibliography read; external abstracts, full text, registrations, protocols and analysis plans unread
Why unverified: Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Original harm methods, events, discontinuations, omissions, comparator and period data are needed. Unread material is not treated as no harms.
Required materials and conditions: Definitions, collection, severity and counts for diarrhea and gastrointestinal discomfort
Materials to obtain first: Original harm methods, events, discontinuations, omissions, comparator and period data are needed. Unread material is not treated as no harms.
Further research: Material needed: Original harm methods, events, discontinuations, omissions, comparator and period data are needed. Unread material is not treated as no harms. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps in original diagnosis, products, individual exposure, arm-specific analyses, TNSS, rescue medication, plans, support and harms remain. Abstract-reported improvement is not converted into an established effect, a lack of skin-wheal difference into a clinical null or equivalence, or limited harm records into overall safety.
Conditions for verification: Original records on Definitions, collection, severity and counts for diarrhea and gastrointestinal discomfort must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Why this condition is needed: Material on Definitions, collection, severity and counts for diarrhea and gastrointestinal discomfort is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

Related sources R01 R02

N26 · Are harm denominators, exposure and comparators distinguished?

Current findings: The 40 people in R01 and the R02 skin-test denominators do not establish safety denominators. Individual R01 exposure duration also remains unverified.
Verification status: Unverified
Materials actually read: Existing Korean and English stored summaries, rhinitis comparison records and skin-test bibliography read; external abstracts, full text, registrations, protocols and analysis plans unread
Why unverified: Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Arm-specific safety denominators, actual dosing/discontinuation, events, exposure and comparator data are needed. Incidence rates are not calculated.
Required materials and conditions: Safety sets, actual use, events and individual exposure duration
Materials to obtain first: Arm-specific safety denominators, actual dosing/discontinuation, events, exposure and comparator data are needed. Incidence rates are not calculated.
Further research: Material needed: Arm-specific safety denominators, actual dosing/discontinuation, events, exposure and comparator data are needed. Incidence rates are not calculated. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps in original diagnosis, products, individual exposure, arm-specific analyses, TNSS, rescue medication, plans, support and harms remain. Abstract-reported improvement is not converted into an established effect, a lack of skin-wheal difference into a clinical null or equivalence, or limited harm records into overall safety.
Conditions for verification: Original records on Safety sets, actual use, events and individual exposure duration must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Why this condition is needed: Material on Safety sets, actual use, events and individual exposure duration is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

Related sources R01 R02

N27 · Are stone, kidney-disease and iron-overload cautions distinguished from direct harms?

Current findings: Existing caution about stone risk, kidney disease and iron overload is retained. It is not converted into certification of trial harm occurrence, causality, contraindications or long-term safety.
Verification status: Partly verified
Materials actually read: Existing Korean and English stored summaries, rhinitis comparison records and skin-test bibliography read; external abstracts, full text, registrations, protocols and analysis plans unread
Why unverified: Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Vulnerable groups, independent harm reports, exposure/denominators, concomitant use/alternative causes and event courses are needed. No new harm search or assessment is performed.
Required materials and conditions: Vulnerable populations, concomitant use, alternative causes and long-term/rare harms
Materials to obtain first: Vulnerable groups, independent harm reports, exposure/denominators, concomitant use/alternative causes and event courses are needed. No new harm search or assessment is performed.
Further research: Material needed: Vulnerable groups, independent harm reports, exposure/denominators, concomitant use/alternative causes and event courses are needed. No new harm search or assessment is performed. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps in original diagnosis, products, individual exposure, arm-specific analyses, TNSS, rescue medication, plans, support and harms remain. Abstract-reported improvement is not converted into an established effect, a lack of skin-wheal difference into a clinical null or equivalence, or limited harm records into overall safety.
Conditions for verification: Original records on Vulnerable populations, concomitant use, alternative causes and long-term/rare harms must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Why this condition is needed: Material on Vulnerable populations, concomitant use, alternative causes and long-term/rare harms is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

Related sources R01 R02

N28 · Are historical abstract checking and PDF failure separated from current unread status?

Current findings: Historical R01 abstract/bibliography checking and PDF access failure, and R02 abstract/bibliography checking, remain historical. Stored summaries were read here; external abstracts, full text, registration and plans were not.
Verification status: Partly verified
Materials actually read: Existing Korean and English stored summaries, rhinitis comparison records and skin-test bibliography read; external abstracts, full text, registrations, protocols and analysis plans unread
Why unverified: Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Current external acquisition, actual reading and review remain outstanding. Historical failure is not converted into current inaccessibility, or historical checking into current reading.
Required materials and conditions: Historical access descriptions, current stored summaries and external-material status
Materials to obtain first: Current external acquisition, actual reading and review remain outstanding. Historical failure is not converted into current inaccessibility, or historical checking into current reading.
Further research: Material needed: Current external acquisition, actual reading and review remain outstanding. Historical failure is not converted into current inaccessibility, or historical checking into current reading. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps in original diagnosis, products, individual exposure, arm-specific analyses, TNSS, rescue medication, plans, support and harms remain. Abstract-reported improvement is not converted into an established effect, a lack of skin-wheal difference into a clinical null or equivalence, or limited harm records into overall safety.
Conditions for verification: Original records on Historical access descriptions, current stored summaries and external-material status must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Why this condition is needed: Material on Historical access descriptions, current stored summaries and external-material status is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

Related sources R01 R02

N29 · Are original Korean/English descriptions and empty correction records preserved?

Current findings: Existing Korean/English descriptions and empty correction/detailed-claim records are preserved. No new correction or completed original-material clinical review is created.
Verification status: Partly verified
Materials actually read: Existing Korean and English stored summaries, rhinitis comparison records and skin-test bibliography read; external abstracts, full text, registrations, protocols and analysis plans unread
Why unverified: Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: New evidence, corrections and verdict changes require preservation of originals and separate event records.
Required materials and conditions: Complete Korean/English originals, empty corrections/detailed claims and original dates
Materials to obtain first: New evidence, corrections and verdict changes require preservation of originals and separate event records.
Further research: Material needed: New evidence, corrections and verdict changes require preservation of originals and separate event records. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps in original diagnosis, products, individual exposure, arm-specific analyses, TNSS, rescue medication, plans, support and harms remain. Abstract-reported improvement is not converted into an established effect, a lack of skin-wheal difference into a clinical null or equivalence, or limited harm records into overall safety.
Conditions for verification: Original records on Complete Korean/English originals, empty corrections/detailed claims and original dates must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Why this condition is needed: Material on Complete Korean/English originals, empty corrections/detailed claims and original dates is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

Related sources R01 R02

N30 · Are original C46, EX/CX and I1 distinguished from production?

Current findings: The existing C·46 points·Caution, original rationale for EX/CX and the I1 operational midpoint, and evidence date 2026-09-07 are retained. Unverified information is not converted into no effect, a precise null, an independence strength or a new grade.
Verification status: Partly verified
Materials actually read: Existing Korean and English stored summaries, rhinitis comparison records and skin-test bibliography read; external abstracts, full text, registrations, protocols and analysis plans unread
Why unverified: Stored information is linked to gaps in detailed material. External verification and clinical content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: New evidence, revised criteria and verdict changes are separate events. The existing date is not used as a current search or external-reading date.
Required materials and conditions: C46, Caution, assessment values, original exception rationale and evidence date
Materials to obtain first: New evidence, revised criteria and verdict changes are separate events. The existing date is not used as a current search or external-reading date.
Further research: Material needed: New evidence, revised criteria and verdict changes are separate events. The existing date is not used as a current search or external-reading date. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps in original diagnosis, products, individual exposure, arm-specific analyses, TNSS, rescue medication, plans, support and harms remain. Abstract-reported improvement is not converted into an established effect, a lack of skin-wheal difference into a clinical null or equivalence, or limited harm records into overall safety.
Conditions for verification: Original records on C46, Caution, assessment values, original exception rationale and evidence date must link to the same question, route, population, comparison, endpoint, timing and analysis denominator, distinguishing recorded information from gaps.
Why this condition is needed: Material on C46, Caution, assessment values, original exception rationale and evidence date is needed to connect the selected rhinitis question to its oral monotherapy formulation, population, placebo, clinical symptoms, timing, denominators, precision, skin-marker boundaries and harms.
Application exceptions: Oral monotherapy symptom effects remain separate from combined exercise, intravenous infusion, combination products, plasma vitamin C and skin wheals. Study-conduct periods are not converted into individual treatment duration; no new arm sizes, effects, intervals, P values, attrition, harm incidence or cumulative doses are calculated.
Referenced methods: Existing principles distinguish questions, populations, oral monotherapy, placebo, clinical symptoms and skin markers, timing, reports and trials, denominators and harms.

Related sources R01 R02